Junko Tanizaki
Overview
Explore the profile of Junko Tanizaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1477
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hakozaki T, Tanaka K, Shiraishi Y, Sekino Y, Mitome N, Okuma Y, et al.
J Thorac Oncol
. 2025 Mar;
PMID: 40058642
Background: Immunotherapy has transformed treatment for non-small cell lung cancer (NSCLC). However, reliable biomarkers for treatment selection remain scarce. Gut microbiota has emerged as a potential biomarker, but its role...
2.
Shukuya T, Asao T, Goto Y, Mimori T, Takayama K, Kaira K, et al.
Lancet Oncol
. 2025 Mar;
26(3):331-342.
PMID: 40049197
Background: Despite the poor prognosis of advanced or recurrent thymic carcinoma, the rarity of thymic carcinoma has delayed the development and introduction of novel pharmacotherapy options. Carboplatin plus paclitaxel remains...
3.
Shiraishi N, Takahama T, Sakai K, Tanaka K, Nakagawa Y, Kanemura H, et al.
Thorac Cancer
. 2025 Feb;
16(3):e70007.
PMID: 39947926
Background: Recognizing rare molecular variants of driver mutations poses a challenge in precision oncology, particularly for treatment of non-small cell lung cancer (NSCLC). In this study, we aimed to determine...
4.
5.
Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, et al.
Mol Clin Oncol
. 2024 Dec;
22(2):14.
PMID: 39720462
We have been exploring biomarkers that could help physicians select the appropriate opioid for individualized treatment of cancer pain. Recently, we identified a single nucleotide polymorphism (SNP) of (rs17809012) as...
6.
Ou S, Le X, Nagasaka M, Reungwetwattana T, Ahn M, Lim D, et al.
Lung Cancer (Auckl)
. 2024 Jun;
15:87-114.
PMID: 38938224
The year 2024 is the 20 anniversary of the discovery of activating epidermal growth factor receptor () mutations in non-small cell lung cancer (NSCLC). Since then, tremendous advances have been...
7.
Hayashi H, Chamoto K, Hatae R, Kurosaki T, Togashi Y, Fukuoka K, et al.
J Clin Invest
. 2024 Apr;
134(7).
PMID: 38557498
BACKGROUNDPrecise stratification of patients with non-small cell lung cancer (NSCLC) is needed for appropriate application of PD-1/PD-L1 blockade therapy.METHODSWe measured soluble forms of the immune-checkpoint molecules PD-L1, PD-1, and CTLA-4...
8.
Haratani K, Nakamura A, Mamesaya N, Sawa K, Shiraishi Y, Saito R, et al.
Br J Cancer
. 2024 Mar;
130(11):1783-1794.
PMID: 38519705
Background: Immune-related adverse events (irAEs) have been found to predict PD-L1 inhibitor efficacy in metastatic NSCLC. However, the relation of irAEs to clinical outcome for nonmetastatic NSCLC has remained unknown....
9.
Imai H, Kijima T, Azuma K, Kishi K, Saito H, Yamaguchi T, et al.
Jpn J Clin Oncol
. 2024 Jan;
54(4):452-462.
PMID: 38271158
Objective: As first-line treatment for stage IV or recurrent non-small cell lung cancer, combination immunotherapy with nivolumab and ipilimumab, with or without chemotherapy, had demonstrated survival benefits over chemotherapy; however,...
10.
Hagiwara S, Tanizaki J, Hayashi H, Komeda Y, Nishida N, Yoshida A, et al.
Cancer Rep (Hoboken)
. 2024 Jan;
7(2):e1960.
PMID: 38196303
Background: Immune checkpoint inhibitors have been reported to have excellent therapeutic effects on various malignant tumors. However, immune-related adverse events can occur, targeting various organs. Case Presentation: A 49-year-old male...